AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 211 min read$ORKA

Quinlan Paul T sold $707K of ORKA

Quinlan Paul T (General Counsel) sold 9,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $78.53 ($74.90–$79.49, $0.71M total) across 5 trades on 2026-10-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Quinlan Paul T
Published Oct 21, 2026, 12:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Bearish
medium confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKABearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency on insider holdings.

02

Market read

Routine insider sale with limited market impact.

03

What to watch

Potential tax planning or liquidity needs unrelated to company performance.

Relevance 4/10Novelty 4/10Timing: after-hours disclosure on 2026‑10‑20

Background

Form 4 filings disclose insider transactions; investors monitor them for signals of confidence or concern.

Company-level read

Ticker impact

$ORKABearishMedium confidence
Context

General Counsel Quinlan Paul T sold 9,000 shares for $706,735 via a 10b5‑1 plan, reducing his stake to 29,995 shares.

Expected impact

likely slight downward pressure as the market absorbs the disclosed sale

Evidence & confidence

Form 4 filing is a primary source, but the transaction size (~$0.7 M) is small relative to market cap, limiting material impact.

Market effects

Sector

Minimal; does not affect broader biotech sector.

Regional

None; confined to ORKA shareholders.

Global

None

Counterpoint

What could challenge this read

The sale may be routine and not indicative of negative fundamentals.

Key entities

  • person
    Quinlan Paul T

    General Counsel of Oruka Therapeutics, Inc.

  • company
    Oruka Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min